Dec 29, 2023, 05:18
U.S. FDA summarizes their decision to restrict the approval of olaparib + abiraterone – American Society of Clinical Oncology (ASCO)
American Society of Clinical Oncology (ASCO) shared on their X/Twitter page:
”Breaking from Journal of Clinical Oncology: U.S. FDA summarizes their decision to restrict the approval of olaparib + abiraterone to patients with BRCA-mutated mCRPC rather than grant approval for all patients. Read in ASCO Daily News.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19